In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

https://www.fosunpharma.com/en/

Latest From Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Henlius Pursues Two-Pronged Approach In Quest For Novel ADCs

Moving decisively but not hurriedly, Henlius is taking a two-pronged approach to join the global ADC race. The first two molecules developed via its in-licensed novel linker-payload platform have entered the clinical stage, while its own proprietary programs are seeing steady R&D progress, the Chinese firm's head of early R&D tells Scrip in an interview.

China Research & Development

China CEO Interview: Gracell Aims To Enter US CAR-T Sector Through Partnerships, Faster Delivery

With the success of the partnership between J&J and partner Legend, more Chinese cell therapy developers are now looking to enter the US market. But for a complex product like a CAR-T therapy, the journey to the West is not short of challenges. Nasdaq-listed Gracell Bio wants to give it a shot based on quicker delivery and cost-effectiveness advantages.

China Business Strategies

Iksuda Aims For Best-In-Class Cancer ADCs With Toolbox Approach To Technology

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.

Emerging Company Profile ImmunoOncology

MPP Facilitates Agreements With Seven Manufacturers For COVID-19 Antiviral

The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.

Coronavirus COVID-19 Intellectual Property
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Pharmaceuticals
    • Vaccines
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Ahon Pharmaceutical Co., Ltd.
    • Fosun Kite Biotechnology Co., Ltd.
    • Fosun Pharma Kite Biotechnology Co. Ltd.
    • Guilin Pharma
    • Jiangsu Wanbang Biopharmaceutical Group Co., Ltd.
    • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    • Shenyang Hongqi Pharmaceuticals Co., Ltd.,
    • Fosun Industrial Co., Limited
UsernamePublicRestriction

Register